Reduced IFN-γ Production in Chronic Brucellosis Patients

Reduced IFN-γ Production in Chronic Brucellosis Patients


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
علوم پزشکی اراک
علوم پزشکی اراک

نویسندگان: نادر زرین فر , احسان اله غزنوی راد , قاسم مسیبی , خدیجه خسروی

کلمات کلیدی: Keywords: Migraine disorders, melatonin, valproic acid

نشریه: Iranian Journal of Immunology, 14,,215 - 222,2017

اطلاعات کلی مقاله
hide/show

کد مقاله 4114
عنوان فارسی مقاله Reduced IFN-γ Production in Chronic Brucellosis Patients
عنوان لاتین مقاله Reduced IFN-γ Production in Chronic Brucellosis Patients
نوع مقاله بر حسب نگارش پژوهشی اصیل
مقاله برحسب نمایه ISI
IF 0.85
عنوان نشریه Iranian Journal of Immunology
نوع نشریه علمی پژوهشی
شماره نشریه 14
دوره 3
صفحه شروع و پایان در نشریه 215 - 222
سال انتشار/ ارائه شمسی 1396
سال انتشار/ارائه میلادی 2017
آدرس لینک مقاله/ همایش در شبکه اینترنت
ISSN 1735-1383
DOI
آدرس علمی (Affiliation) نویسنده متقاضی 1Molecular and Medicine Research Center (MMRC), Department of Microbiology and Immunology,

چکیده مقاله
hide/show

عنوان متن
چکیده انگلیسیt. Background: Melatonin is known to be effective in curing migraine. Objective: This study aimed to investigate the therapeutic effect of melatonin versus sodium valproate in the prophylaxis of chronic migraine. Methods: This randomized, double-blind, placebo-controlled clinical trial included patients with chronic migraine who were divided into three equal sized groups, and baseline therapy with nortriptyline (10–25 mg) and propranolol (20–40 mg) was used. Patients in groups A, B, and C were adjunctively treated daily with 3 mg melatonin, 200 mg sodium valproate, and a placebo, respectively. The patients underwent treatment for 2 months and follow-up was done at baseline (baseline), first (I) and second month (II). Attack frequency (AF), attack duration, attack severity, Migraine Disability Assessment (MIDAS) score (within 3 months in two steps), analgesic intake, and drug side effects between the groups and during follow-up were compared. Results: The mean of monthly AF (melatonin: baseline: 4.2, I: 3.1, II: 2.5, p = 0.018; valproate: baseline: 4.3, I: 3.1, II: 2.3, p = 0.001; placebo: baseline: 4.1, I: 3.8, II: 3.8 p = 0.211), attack duration (hr) (melatonin: baseline: 19.8, I: 10.1, II: 8.7, p < 0.001; valproate: baseline: 19.5, I: 10.2, II: 8.8, p < 0.001; placebo: baseline: 19.6, I: 15.4, II: 14.1, p = 0.271), attack severity (melatonin: baseline: 7.3, I: 5.4, II: 3.5, p < 0.001; valproate: baseline: 7.4, I: 5.3, II: 3.4, p = 0.000; placebo: baseline: 7.3, I: 6.4, II: 6, p = 0.321), and MIDAS score (melatonin: baseline: 15.2, II: 8.9, p = 0.005; valproate: baseline: 16.1, II: 8.3, p = 0.001; placebo: baseline: 16, II: 12.1, p = 0.44), were significantly reduced in the melatonin and sodium valproate groups, but not in the placebo groups. Adverse events were reported in 11 patients (10.47%): 2 (5.71%) during melatonin treatment, 8 (22.85%) during valproate, and 1 (2.85%) during placebo. Conclusion: The adjuvant treatment with melatonin was found to be superior to the placebo and had the same clinical efficacy as sodium valproate, but with higher tolerability. Melatonin may prove to be an efficient substitute for sodium valproate, as a chronic migraine prophylaxis. K
چکیده
کلمات کلیدیKeywords: Migraine disorders, melatonin, valproic acid
نام فایل عنوان پیوست تاریخ درج فایل اندازه فایل دانلود

نویسندگان
hide/show

نویسنده نفر چندم مقاله
نادر زرین فرسوم
احسان اله غزنوی راداول
قاسم مسیبیچهارم و مسئول
خدیجه خسرویدوم

لینک دانلود مقاله
hide/show

نام فایل عنوان پیوست تاریخ درج فایل اندازه فایل دانلود
Reduced IFN Production in Chronic brucellosis- Mosayebi et al.pdfمتن کامل مقاله1396/07/19277930دانلود
12.pdf 1396/09/28226024دانلود
14.pdfJCR مجله1396/09/28237339دانلود